Oral Transmucosal Drugs Market Share, Size, Trends, Industry Analysis Report, By Product Type (Tablets, Films), By Route of Administration, By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2032

Oral Transmucosal Drugs Market Share, Size, Trends, Industry Analysis Report, By Product Type (Tablets, Films), By Route of Administration, By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2032

The global oral transmucosal drugs market size is expected to reach USD 82.99 billion by 2032, according to a new study by Polaris Market Research. The report “Oral Transmucosal Drugs Market Share, Size, Trends, Industry Analysis Report, By Product Type (Tablets, Films), By Route of Administration, By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The surge in research and development endeavors, coupled with new product launches and an increase in the prevalence of targeted diseases, is poised to propel market growth. Additionally, the growth in the target population is expected to contribute to the market's expansion. The unique formulation of oral transmucosal fentanyl citrate, incorporating fentanyl in a lozenge for drug delivery through the buccal mucosa, offers enhanced bioavailability compared to the oral route by bypassing first-pass metabolism.

Consequently, the growing opioid dependence within the patient population seeking immediate relief from pain associated with various disorders is likely to drive the demand for oral transmucosal drugs, for example, as per the World Health Organization's data from 2021, around 275 million people globally used medications, with approximately 62 million among them using opioids.

The growing prevalence of Parkinson's disease (PD) and migraine is anticipated to drive the expansion of the market. For instance, data from the Parkinson's Foundation, January 2022, reveals that nearly one million people in the United States are currently living with Parkinson's disease, with projections indicating an increase to around 1.2 Mn by 2030. Parkinson's disease stands as the second-most common neurodegenerative disease, following Alzheimer's disease, with over 60,000 Americans diagnosed annually and a global population exceeding 10 Mn individuals living with PD. The rising incidences of such disorders are likely to boost the adoption of oral transmucosal drugs for their treatment, leading to improved pain management and immediate relief.

As of January 2021, data from the CDC indicates that 26% of adults aged 65 or older had eight or fewer teeth, and approximately 1 in 6 (17%) adults in the same age group had lost all their teeth in the United States. Additionally, according to CDC data from February 2022, 63% of adults aged 18 and over in the United States had a dental visit in the past year, and 85.9% of children aged 2-17 years had a dental visit in the year 2020. This rise in dental visits is expected to fuel the demand for oral transmucosal drugs, such as midazolam and buprenorphine, for sedation and pain relief.

Oral Transmucosal Drugs Market Report Highlights

Tablets segment held the largest share, owing to its ease of use, easy absorption, and have higher efficiency

Opioid dependence segment dominated the market, primarily due to rising cases of opioid disorders

Sub-lingual drugs garnered the largest share, as they are mostly preferred during acute pain conditions

APAC expected to grow at the fastest rate, due to presence of huge population suffering with stress and mental conditions

The market players include Aquestive Therapeutics, C.L. Pharm, GW Pharmaceuticals, IntelGenx, Pfizer, Seoul Pharmaceuticals, and Shilpa Therapeutics

Polaris Market Research has segmented the oral transmucosal drugs market report based on product type, route of administration, indication, distribution channel, and region:

Oral Transmucosal Drugs, Product Type Outlook (Revenue - USD Billion, 2019 - 2032)

Tablets

Films

Liquid & Spray

Others

Oral Transmucosal Drugs, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

Sublingual Mucosa

Buccal Mucosa

Others

Oral Transmucosal Drugs, Indication Outlook (Revenue - USD Billion, 2019 - 2032)

Opioid Dependence

Nausea and Vomiting

Erectile Dysfunction

Neurological Disorders

Others

Oral Transmucosal Drugs, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Oral Transmucosal Drugs, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa